66th Annual Scientific Sessions of the American College of Cardiology 2017

The Word from ACC 2017 – Implications for Practice

The highlight of ACC 2017 was the FOURIER trial, representing the culmination of the PCSK9 revolution. Here PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board discuss implications from FOURIER for clinical practice.

The Word from ACC 2017 – Key Results

The highlight of ACC 2017 was the FOURIER trial, representing the culmination of the PCSK9 revolution. Here PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board dissect the key results and messages from FOURIER.

VIDEO: Access to PCSK9 inhibitor treatment: NLA survey provides important pointers

Professor Dean G. Karalis (Director of Preventive Cardiology, Pennsylvania Hospital, USA) discusses the issues and how to counter these. FOURIER and SPIRE-2 have clearly shown the benefits of lowering LDL cholesterol beyond current targets in very high risk patients. However, from a routine practice view,…

FOURIER in the Hot Seat: What are the Implications for practice and access?

FOURIER was a landmark trial for PCSK9 inhibition, showing significant reduction in cardiovascular events with evolocumab in very high risk patients on maximally tolerated lipid lowering therapy. The results from FOURIER, together with those from SPIRE-2 in patients at higher baseline LDL cholesterol levels, clearly…

Dr Brian Ference sets the record straight on questions about benefit in FOURIER

In discussions at ACC.2017, some have suggested that the results of FOURIER were less than anticipated from the meta-analysis of statin trials by the Cholesterol Treatment Trialists’ Collaboration (CTTC) (1). PCSK9 Forum Editor Dr Brian Ference (Division of Cardiovascular Medicine, Wayne State University School of…

Events are the driver in PCSK9 cardiovascular outcomes trials

A recurrent question at ACC.2017 was why FOURIER had a short duration of follow-up, given the average duration of the statin trials was typically in the region of 4-5 years. This debate has been fanned by colourful but misinformed reports in the investment media (1).’…

Prof Evan Stein: What are the key messages from FOURIER?

Prof Ulf Landmesser: How can we ensure the best value from PCSK9 inhibitor therapy?

Prof Steve Nicholls: How can FOURIER improve our clinical practice?

Prof Ulf Landmesser: How will FOURIER impact practice?

Prof Steve Nicholls: Is there a link between the benefit of evolocumab observed in GLAGOV & FOURIER?

Prof Steve Nicholls: Is FOURIER a game changer?

Prof Robert Rosenson: REGARDS study adds to EBBINGHAUS reassures on lack of effect on neurocognition at low LDL-C

In a new report today, Professor Robert Rosenson (Mount Sinai Icahn School of Medicine, Mount Sinai Hospita, New York, USA) discusses results from the REGARDS study. This study investigated whether there was any link between PCSK9 genetic variants associated with low LDL cholesterol and cognitive…

EBBINGHAUS counters claim of neurocognitive effects with PCSK9 inhibition

Ebbinghaus was a pioneer of memory research. One of his key contributions was the forgetting curve, which describes the exponential loss of learned information. It is therefore fitting that a trial bearing his name has shown that very low LDL cholesterol levels on PCSK9 monoclonal…

VIDEO: Prof Raul Santos: How can PCSK9 monoclonal antibody therapy be cost effective?

Prof Francois Mach: How will FOURIER impact guidelines

Prof Francois Mach discusses EBBINGHAUS

Prof Raul Santos: Do PCSK9 inhibitors have adverse effects on neurocognition

SPIRE trials: Bococizumab was insufficiently humanized for long-term use

The development of bococizumab, the third of the PCSK9 monoclonal antibodies, was discontinued by Pfizer in early November (1). Insights from a late breaker trial presentation provide some answers why this might be the case. SPIRE programme: lipid lowering trials The SPIRE program included 6…

SPIRE-2: Cardiovascular benefit in very high risk patients

Evidence from the two cardiovascular outcomes studies with bococizumab, notably SPIRE-2, added to the buzz around FOURIER. According to PCSK9 Forum Editor Professor Philip Barter (University of New South Wales, Sydney, Australia): ‘Despite follow-up being short due to termination of the development of bococizumab, SPIRE-2…